The flu is a health risk for Canadians. It causes up to 15,000 hospitalizations every year and is one of the top 10 causes of death. Getting a flu vaccine is the best way to prevent the flu and any severe complications. Unfortunately, many Canadians do not get the flu vaccine. A recent survey found that less than a quarter of healthy adults got the flu vaccine.
In Canada, current standard access to influenza vaccination is at physician offices, public health clinics, or pharmacy. Therefore, this study is testing a novel access route to influenza vaccine. This study will answer the question: "Will self-administration at home of FLUMIST through a pharmacy pick up model increase uptake of influenza vaccination compared to usual care?" FLUMIST is a needle-free vaccine given as a nasal spray.
Households will be randomly chosen to either be offered the FLUMIST vaccine that can be given at home or to make their own choice for the flu season, which may or may not include vaccination.
None
Pregnancy
Breast feeding
Past serious allergic reaction to study vaccine components (including gentamicin, gelatin, or arginine) or to previous influenza vaccination
Severe asthma or active wheezing
Parallel
LAIV FLUMIST
Biological/VaccineChildren, adolescents, adults 9 to 59 years - 1 dose (0.2 ml).
Vaccine uptake
To assess whether self-administration at home of FLUMIST through a pharmacy pick up model can increase uptake of influenza vaccination compared to usual care.
Independent factors predictive of influenza uptake
Secondary objectives will be to determine independent factors predictive of influenza uptake.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
